Ibcasertib
As of the edition of 20 October 2026, Ibcasertib is a small molecule: in active development; acts on AURKB, FLT1 and FLT4 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 17, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Hormones; Pregnancy and women's health; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 9 | 6 | 1 | 1 |
| Phase 3 | 3 | 1 | 2 | 0 |
| All trials | 17 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chipscreen Biosciences | Lead sponsor of trials | 2014 to now |
| Akeso | Lead sponsor of trials | 2022 to now |